Progress of CDK4/6 inhibitors in the treatment of malignant tumors

• Main Authors: Bin Fu, Zhen Rong
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2019-11-01
• Series: Journal of Hainan Medical University
• Subjects: cdk4/6 inhibitor; molecular targeted drug; cancer treatment; lung cancer; breast cancer
• Online Access: http://www.hnykdxxb.com/PDF/201911/16.pdf

CDK4/6 inhibitor acts on cell cycle. It can be used alone or in combination to treat lung cancer, liver cancer, pancreatic cancer and other cancers by restoring normal cell cycle, triggering antitumor immunity and changing the microenvironment of tumors. It has a certain therapeutic effect, and has a certain inhibitory effect on the proliferation and development of malignant tumors. The combination of other antineoplastic drugs can effectively reduce the emergence of drug resistance and synergistically enhance the clinical efficacy. This article reviews the related research results of CDK4/6 inhibitors, as well as the literature, and summarizes the mechanism and clinical application of CDK4/6 inhibitors. Cyclin dependent kinase (CDK) is a group of serine/threonine protein kinases. The chemical action of CDK on serine/threonine protein is the key to driving cell cycle. The typical biological feature of cancer is cell cycle disorder. As the engine of cell cycle, CDK and its regulators play an important role in tumorigenesis and development. In modern times, cancer has gained a deeper understanding at the level of biomolecule. For cell receptors, more and more drugs are used for key genes. The new generation of CDK4/6 inhibitors cut into the cell cycle to treat malignant tumors, prevent cells from G1 phase to S phase. They have good clinical efficacy for ER + breast cancer patients. They are also used in clinical trials of lung cancer, melanoma and other malignant tumors to treat malignant tumors. Therapy provides a new way.